Skip to main content
Premium Trial:

Request an Annual Quote

RBM to Develop, Sell Schizophrenia Biomarker Test with Psynova Neurotech

NEW YORK (GenomeWeb News) – Rules-Based Medicine said today it will work with start-up drug firm Psynova Neurotech to develop and sell a biomarker-based blood test that could be used to help diagnose schizophrenia. 
The companies will work together to validate, seek regulatory approval for, and manufacture the schizophrenia test, which RBM will sell exclusively worldwide.
Psynova discovered the biomarkers the companies will test through a collaboration with the Cambridge Centre for Neuropsychiatric Research at the Institute of Biotechnology, Cambridge University. Those collaborators processed samples using RBM’s HumanMAP multiplex platform.
Current diagnosis of schizophrenia is highly subjective and time consuming, the company said, and the biomarker-based tests will help general practitioners and psychiatrists diagnose and treat patients early on, while their symptoms are mild.
Psynova Neurotech was founded by University of Cambridge researchers Sabine Bahn and Chris Lowe, and was funded by Porton Capital.
Financial terms of the agreement were not released.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.